Cymbimicin A and B, two novel cyclophilin-binding structures isolated from actinomycetes.
Two novel metabolites, cymbimicins A and B, were isolated from the culture broth of a strain of Micromonospora sp. by screening for cyclophilin binding metabolites from actinomycete strains. Cymbimicin A binds to cyclophilin A with a high affinity six fold lower than to that of cyclosporin A. The binding affinity of cymbimicin B is about 100 times lower. The taxonomy of the producing strain, fermentation, isolation, physical and biological properties and structure elucidation are described.
Fehr
T
T
Novartis Pharma Inc., Preclinical Research, Basel, Switzerland.
Quesniaux
V F
VF
Sanglier
J J
JJ
Oberer
L
L
Gschwind
L
L
Ponelle
M
M
Schilling
W
W
Wehrli
S
S
Enz
A
A
Zenke
G
G
Schuler
W
W
D001667:Binding, Competitive / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005285:Fermentation; D007166:Immunosuppressive Agents / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D007783:Lactones / Q000737:chemistry / Q000302:isolation & purification* / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D008847:Micromonospora / Q000737:chemistry* / Q000378:metabolism; D019696:Peptidylprolyl Isomerase / Q000378:metabolism
D007166:Immunosuppressive Agents; D007783:Lactones; C111286:cymbimicin A; C111287:cymbimicin B; D019696:Peptidylprolyl Isomerase